- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Foghorn Therapeutics Inc (FHTX)
Foghorn Therapeutics Inc stock price live, this page displays NASDAQ FHTX stock exchange data. View the FHTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Foghorn Therapeutics Inc real time stock price chart below.
What Is the Foghorn Therapeutics Inc Stock Price Today?
The Foghorn Therapeutics Inc stock price today is 4.59.
What Is the Stock Symbol for Foghorn Therapeutics Inc?
The stock symbol for Foghorn Therapeutics Inc is ""FHTX.""
What Stock Exchange Does Foghorn Therapeutics Inc Trade On?
Foghorn Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Foghorn Therapeutics Inc a Good Stock to Buy?
Determining whether Foghorn Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FHTX quote. (ISIN: US3441741077)
What Is the Foghorn Therapeutics Inc Stock Price Today?
The Foghorn Therapeutics Inc stock price today is 4.59.
What Is the Stock Symbol for Foghorn Therapeutics Inc?
The stock symbol for Foghorn Therapeutics Inc is ""FHTX.""
What Stock Exchange Does Foghorn Therapeutics Inc Trade On?
Foghorn Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Foghorn Therapeutics Inc a Good Stock to Buy?
Determining whether Foghorn Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FHTX quote. (ISIN: US3441741077)
NASDAQ
Currency in USD
4.59
-0.39(-7.83%)
Closed·
After Hours
4.580.00(0.00%)
·
Fair Value
An estimate of a Foghorn's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.47
5.02
52 wk Range
2.94
10.25
FHTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
FHTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Foghorn's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.475.02
52 wk Range
2.9410.25
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FHTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Foghorn's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
11.67
Upside
+154.18%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings upwards for the upcoming period
- Ted Myles Joins Cellarity as Chief Executive Officer
- Investing.com
- Citizens JMP reiterates Foghorn stock with $9 target
- Investing.com
- Citizens JMP reiterates Foghorn stock with $9 target
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Foghorn Therapeutics Inc Company Profile
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Foghorn Therapeutics Inc SWOT Analysis
Chromatin Pionee | Foghorn Therapeutics leads in chromatin biology, targeting cancer through gene expression regulation with innovative BAF complex-focused pipeline |
Pipeline Potential | FHD-286 and FHD-909 programs show promise in AML and BRG1 loss-of-function cancers, with crucial data releases anticipated in Q4 2024 |
Eli Lilly Backing | $300 million upfront payment from Eli Lilly partnership validates Foghorn's technology and provides substantial financial resources for development |
Market Outlook | Analyst targets range from $9 to $20, with a strong buy consensus. Total addressable market estimated in tens of billions, despite current volatility |
Compare FHTX to Peers and Sector
Metrics to compare | FHTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFHTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | −0.4x | −0.5x | |
PEG Ratio | −0.10 | −0.01 | 0.00 | |
Price/Book | −3.4x | 2.7x | 2.6x | |
Price / LTM Sales | 10.7x | 8.7x | 3.3x | |
Upside (Analyst Target) | 130.9% | 318.4% | 43.4% | |
Fair Value Upside | Unlock | 7.1% | 7.1% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.67
(+154.18% Upside)
Earnings
Latest Release
Aug 05, 2025
EPS / Forecast
-0.28 / -0.3514
Revenue / Forecast
7.56M / 6.49M
People Also Watch
FAQ
What Stock Exchange Does Foghorn Trade On?
Foghorn is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Foghorn?
The stock symbol for Foghorn is "FHTX."
What Is the Foghorn Market Cap?
As of today, Foghorn market cap is 281.52M.
What Is Foghorn's Earnings Per Share (TTM)?
The Foghorn EPS (TTM) is -1.20.
When Is the Next Foghorn Earnings Date?
Foghorn will release its next earnings report on 10 Nov 2025.
From a Technical Analysis Perspective, Is FHTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Foghorn Stock Split?
Foghorn has split 0 times.
How Many Employees Does Foghorn Have?
Foghorn has 112 employees.
What is the current trading status of Foghorn (FHTX)?
As of 08 Aug 2025, Foghorn (FHTX) is trading at a price of 4.59, with a previous close of 4.98. The stock has fluctuated within a day range of 4.47 to 5.02, while its 52-week range spans from 2.94 to 10.25.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.